Geron Corporation (GERN)
NASDAQ: GERN · IEX Real-Time Price · USD
4.170
-0.170 (-3.92%)
At close: Jul 2, 2024, 4:00 PM
4.160
-0.010 (-0.24%)
After-hours: Jul 2, 2024, 7:42 PM EDT
Geron Employees
Geron had 141 employees as of December 31, 2023. The number of employees increased by 34 or 31.78% compared to the previous year.
Employees
141
Change (1Y)
34
Growth (1Y)
31.78%
Revenue / Employee
$3,688
Profits / Employee
-$1,428,333
Market Cap
2.47B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 141 | 34 | 31.78% |
Dec 31, 2022 | 107 | 35 | 48.61% |
Dec 31, 2021 | 72 | 17 | 30.91% |
Dec 31, 2020 | 55 | 9 | 19.57% |
Dec 31, 2019 | 46 | 28 | 155.56% |
Dec 31, 2018 | 18 | 0 | - |
Dec 31, 2017 | 18 | 0 | - |
Dec 31, 2016 | 18 | -2 | -10.00% |
Dec 31, 2015 | 20 | -22 | -52.38% |
Dec 31, 2014 | 42 | -4 | -8.70% |
Dec 31, 2013 | 46 | -59 | -56.19% |
Dec 31, 2012 | 105 | -73 | -41.01% |
Dec 31, 2011 | 178 | 3 | 1.71% |
Dec 31, 2010 | 175 | 3 | 1.74% |
Dec 31, 2009 | 172 | 13 | 8.18% |
Dec 31, 2008 | 159 | 19 | 13.57% |
Dec 31, 2007 | 140 | 37 | 35.92% |
Dec 31, 2006 | 103 | 13 | 14.44% |
Dec 31, 2005 | 90 | 24 | 36.36% |
Dec 31, 2004 | 66 | 13 | 24.53% |
Dec 31, 2003 | 53 | -39 | -42.39% |
Dec 31, 2002 | 92 | -50 | -35.21% |
Dec 31, 2001 | 142 | 30 | 26.79% |
Dec 31, 2000 | 112 | 9 | 8.74% |
Dec 31, 1999 | 103 | 6 | 6.19% |
Dec 31, 1998 | 97 | 8 | 8.99% |
Dec 31, 1997 | 89 | 0 | - |
Dec 31, 1996 | 89 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Bausch Health Companies | 20,270 |
Tandem Diabetes Care | 2,400 |
agilon health | 1,117 |
PTC Therapeutics | 995 |
Agios Pharmaceuticals | 386 |
Rhythm Pharmaceuticals | 226 |
Celldex Therapeutics | 160 |
IDEAYA Biosciences | 124 |
GERN News
- 12 days ago - Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 25 days ago - Geron Stock Soars on FDA Approval of Drug for Patients With Rare Blood Cancers - Investopedia
- 25 days ago - Geron Corp stock opened 25% up on Friday: here's why - Invezz
- 25 days ago - Very good news for Geron stock price: now what? - Invezz
- 25 days ago - Geron shares surge after U.S. FDA approves blood disorder drug - Reuters
- 26 days ago - Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia - Business Wire
- 2 months ago - Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights - Business Wire
- 2 months ago - Geron to Announce First Quarter 2024 Financial Results on May 2, 2024 - Business Wire